Program offers biotechnology developers access to extensive scientific expertise and a wide ecosystem of discovery, development and manufacturing capabilities WILMINGTON, Mass. / Dec 05, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of the Charles River Incubator Program (CIP), specializing in supporting early-stage biotechnology companies in the discovery,... Read More

WILMINGTON, Mass. / Dec 02, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the 7 th Annual Evercore ISI HealthCONx Conference on Wednesday, December 4 th , at 10:00 a.m. ET. Management will provide an overview of Charles River’s strategic focus, business developments, and recent trends. A live webcast of the presentation will be available through a... Read More

WILMINGTON, Mass. / Nov 11, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the UBS Global Healthcare Conference on Tuesday, November 12 th , at 10:15 a.m. PT (1:15 p.m. ET), and the Jefferies London Healthcare Conference on Wednesday, November 20 th , at 2:00 p.m. GMT (9:00 a.m. ET). Management will provide an overview of Charles River’s strategic... Read More

Third-Quarter Revenue of $1.01 Billion Third-Quarter GAAP Earnings per Share of $1.33 and Non-GAAP Earnings per Share of $2.59 Updates 2024 Guidance WILMINGTON, Mass. / Nov 06, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of 2024. For the quarter, revenue was $1.01 billion, a decrease of 1.6% from $1.03 billion in the third quarter of 2023.... Read More

First-in-class in vitro library assesses off-target binding to de-risk in vivo studies WILMINGTON, Mass. / Oct 17, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of the Retrogenix ® Non-Human Protein Library . The non-human protein library helps biopharmaceutical clients assess off-target binding to a non-human proteome to de-risk in vivo studies and aid in... Read More

WILMINGTON, Mass. / Oct 16, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) will release third-quarter 2024 financial results on Wednesday, November 6 th , before the market opens. A conference call has been scheduled to discuss this information on Wednesday, November 6 th , at 9:30 a.m. ET. Investors will have the opportunity to listen to a live webcast of the conference call through the... Read More

WILMINGTON, Mass. / Oct 03, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of neuroscience drug discovery experts will present 18 scientific posters, both independently and collaboratively with clients, at Neuroscience 2024, the annual meeting of the Society for Neuroscience (SfN). The meeting, which brings together leading researchers from across the globe,... Read More

Logica ® , an offering from Charles River and Valo Health, will be leveraged to progress Lundbeck’s research into disorders of the central nervous system WILMINGTON, Mass. / Oct 02, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today announced an agreement with H. Lundbeck A/S (Lundbeck) to utilize Logica ® to progress critical brain disease research. “We are excited to partner with... Read More

As part of the DanubeNeuro program, Charles River and CEBINA will accelerate innovative approaches to treating neurodegenerative diseases WILMINGTON, Mass. & VIENNA / Sep 17, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) and CEBINA GmbH, Central European Biotech Incubator and Accelerator, today announced a strategic collaboration within the acceleration program DanubeNeuro, an initiative... Read More

Collaboration stands to advance novel therapeutic applications across multiple neurologic conditions WILMINGTON, Mass. & MIAMI & HAIFA, Israel / Sep 04, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) and Insightec, a global healthcare company dedicated to using focused ultrasound to transform patient care, today announced the launch of a five-year strategic collaboration to provide Charles... Read More

WILMINGTON, Mass. / Sep 03, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at two upcoming investor conferences, including: Morgan Stanley 22 nd Annual Global Healthcare Conference on Thursday, September 5 th , at 9:15 a.m. EDT; and Baird 2024 Global Healthcare Conference on Tuesday, September 10 th , at 10:15 a.m. EDT. Management will present an... Read More

Second-Quarter Revenue of $1.03 Billion Second-Quarter GAAP Earnings per Share of $1.74 and Non-GAAP Earnings per Share of $2.80 Board Approves New Stock Repurchase Authorization of $1.0 Billion Revises 2024 Guidance WILMINGTON, Mass. / Aug 07, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the second quarter of 2024. For the quarter, revenue was $1.03... Read More

Clinical trials for AAV9 gene therapy bolstered with plasmid and viral vector CDMO expertise WILMINGTON, Mass. / Jul 30, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) announced today a collaboration with the FOXG1 Research Foundation (FRF) highlighting the patient advocacy group’s model to independently drive drug development through the clinical phase. The parent-led global organization... Read More

Agreement establishes Charles River as the preferred partner for Autobahn Labs, leveraging drug discovery and development capabilities to accelerate the translation of academic discoveries into novel therapeutics Under the agreement, Charles River will make an equity investment in Autobahn Labs Justin Bryans, Chief Scientific Officer, Discovery at Charles River, named to Autobahn’s Board of Directors WILMINGTON, Mass. & SAN... Read More

WILMINGTON, Mass. / Jul 16, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2024 financial results on Wednesday, August 7 th , before the market opens. A conference call has been scheduled to discuss this information on Wednesday, August 7 th , at 9:00 a.m. ET. Investors will have the opportunity to listen to a live webcast of the conference call through the... Read More

Critical starting material manufacture for therapeutic targeting high unmet need ophthalmology indication WILMINGTON, Mass. / Jul 08, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) and AAVantgarde today announced a contract development and manufacturing organization (CDMO) agreement to produce Good Manufacturing Practice- (GMP) plasmid DNA. AAVantgarde, a clinical-stage biotechnology... Read More

Lentiviral vector CDMO collaboration to support advanced cell therapies for hematological cancers ROCKVILLE, Md. / Jun 25, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) and the Gates Institute at the University of Colorado Anschutz Medical Campus today announced a lentiviral vector contract development and manufacturing organization (CDMO) agreement. Gates Institute will leverage Charles... Read More

Leveraging CGT CDMO expertise to support T-cell immunotherapy clinical trial WILMINGTON, Mass. / Jun 17, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) and Captain T Cell, a spinoff from the renowned Max Delbrück Center Berlin, Germany, today announced a plasmid DNA and retrovirus vector production program agreement. As part of Charles River’s Cell and Gene Therapy (CGT) Accelerator Program... Read More

Project will utilize an integrated approach to develop an in vitro alternative to inhalation toxicology studies WILMINGTON, Mass. / Jun 11, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today announced a multidisciplinary program, funded through a $1.3 million grant from the Foundation for Chemistry Research & Initiatives (FCRI), in coordination with the American Chemistry Council’s... Read More

New turnkey research facility will provide AAALAC-accredited flexible vivarium space for Massachusetts biopharmaceutical hub WILMINGTON, Mass. / Jun 06, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) has announced the opening of a new Charles River Accelerator and Development Lab (CRADL ® ) facility on Chestnut Street in Somerville, Massachusetts, an emerging life sciences hub. The facility... Read More

Through ongoing collaboration with Sanofi, Charles River will explore use of Virtual Control Groups in nonclinical toxicology WILMINGTON, Mass. / Jun 04, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its Virtual Control Groups (VCG) initiative with Sanofi. The companies are working together to reduce animal usage by replacing selected control group animals... Read More

WILMINGTON, Mass. / Jun 03, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the William Blair 44 th Annual Growth Stock Conference on Tuesday, June 4 th , at 10:00 a.m. CT (11:00 a.m. ET), and at the Jefferies Global Healthcare Conference on Wednesday, June 5 th , at 10:00 a.m. ET. Management will present an overview of Charles River’s strategic focus,... Read More

Fast Track and Modular frameworks facilitate product development continuity via seamless process transfer to the Company’s viral vector Center of Excellence WILMINGTON, Mass. / May 30, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today announced the introduction of its Modular and Fast Track viral vector technology (tech) transfer frameworks. Based on decades of viral vector contract... Read More

First-Quarter Revenue of $1.01 Billion First-Quarter GAAP Earnings per Share of $1.30 and Non-GAAP Earnings per Share of $2.27 Updates 2024 Guidance WILMINGTON, Mass. / May 09, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2024. For the quarter, revenue was $1.01 billion, a decrease of 1.7% from $1.03 billion in the first quarter of 2023.... Read More

Supporting scale-up for early-phase AAV- and LVV-based gene and gene-modified cell therapy researchers and developers WILMINGTON, Mass. / May 02, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its reference materials for adeno associated virus (AAV) and lentiviral vector (LVV) portfolio, designed to streamline Cell and Gene Therapy (CGT) research and... Read More

Company marks significant progress towards climate goals, reaching the milestone considerably ahead of schedule WILMINGTON, Mass. / Apr 22, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today announced it has reached 100 percent renewable electricity across all of its global sites as of the first quarter of 2024, significantly ahead of the original target date. In 2020, Charles River... Read More

Initiative focuses on innovation, partnerships, and advocacy as part of $500 million investment in driving change WILMINGTON, Mass. / Apr 16, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it is launching its Alternative Methods Advancement Project (AMAP), an initiative dedicated to developing alternatives to reduce animal testing. The initiative aims to drive the new... Read More

WILMINGTON, Mass. / Apr 12, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2024 financial results on Thursday, May 9 th , before the market opens. A conference call has been scheduled to discuss this information on Thursday, May 9 th , at 8:30 a.m. ET. Investors will have the opportunity to listen to a live webcast of the conference call through the Investor... Read More

Powered by digital pathology and AI algorithms, Patholytix Foresight drives speed and quality in toxicologic pathology practices WILMINGTON, Mass. & DUBLIN / Apr 11, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of Patholytix Foresight, a non-clinical artificial intelligence (AI) decision support tool developed in collaboration with Deciphex, an innovator in... Read More

HQ plasmid DNA production to support Phase I trials for gene therapy targeting Bardet-Biedl Syndrome WILMINGTON, Mass. / Apr 09, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration with Axovia Therapeutics Ltd . Charles River will manufacture High Quality (HQ) gene of interest plasmid to... Read More

GMP grade plasmid DNA to serve as a direct therapeutic targeting various indications WILMINGTON, Mass. / Apr 04, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) and Ship of Theseus , a therapeutics company developing degradation-resistant homeobox (HOX) family biologics, today announced a Good Manufacturing Practice- (GMP) plasmid DNA contract development and manufacturing organization... Read More

Researchers highlight translational services to optimize drug development programs WILMINGTON, Mass. / Apr 01, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) announced today that its industry-leading team of oncology experts will attend the American Association for Cancer Research (AACR) Annual Meeting . Charles River will present technology-driven capabilities and highlight the latest... Read More

ESG progress includes $200M investment in alternative testing methods; achievement of 92% renewable energy usage worldwide WILMINGTON, Mass. / Mar 27, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today announced the publication of its 2023 Corporate Citizenship Report , which includes progress and results from 2022 and 2023. The 2023 report demonstrates Charles River’s priorities and... Read More

Collaboration provides phase-appropriate plasmid DNA to support the development of engineered stem cells for cancer therapy WILMINGTON, Mass. / Mar 21, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) and National University of Singapore’s (NUS) Yong Loo Lin School of Medicine (NUS Medicine), a leading medical education institution with a world-renowned medical research field of stem cell... Read More

Next-generation AAV gene therapy to target debilitating pain disorders WILMINGTON, Mass. / Mar 14, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) and Navega Therapeutics , Inc., a biotechnology company developing epigenetic gene therapies, today announced an AAV9 production program agreement. As part of Charles River’s Cell and Gene Therapy (CGT) Accelerator Program (CAP), Navega will have... Read More

WILMINGTON, Mass. / Mar 12, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Barclays 26 th Annual Global Healthcare Conference on Wednesday, March 13 th , at 10:15 a.m. ET. Management will present an overview of Charles River’s strategic focus, business developments, and recent trends. A live webcast of the presentation will be available through a... Read More

WILMINGTON, Mass. and OKLAHOMA CITY , Feb. 29, 2024 /PRNewswire/ -- Wheeler Bio, Inc. , an agile contract development and manufacturing organization (CDMO), announced today a new strategic agreement with Charles River Laboratories International, Inc. (NYSE: CRL), a global leader in pharma services, to offer Wheeler Bio's Portable CMC® (Chemistry, Manufacturing and Controls) platform to Charles River Laboratory clients. The... Read More

WILMINGTON, Mass. & OKLAHOMA CITY / Feb 21, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today announced a strategic agreement with Wheeler Bio, Inc., an antibody contract development and manufacturing organization (CDMO) focused on preclinical and early clinical supply of recombinant proteins, providing clients access to Wheeler’s Portable CMC ® (Chemistry, Manufacturing and Controls)... Read More

The addition of ES cells and iPSCs will enhance Charles River’s portfolio of powerful research tools supporting acceleration of therapeutic development. WILMINGTON, Mass. / Feb 20, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into an agreement with Pluristyx Inc. , a leading provider of tools, technologies, and services for the development of cell... Read More

Fourth-Quarter Revenue of $1.01 Billion and Full-Year Revenue of $4.13 Billion Fourth-Quarter GAAP Earnings per Share of $3.62 and Non-GAAP Earnings per Share of $2.46 Full-Year GAAP Earnings per Share of $9.22 and Non-GAAP Earnings per Share of $10.67 Provides 2024 Guidance WILMINGTON, Mass. / Feb 14, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the... Read More

Endosafe ® Trillium™ recombinant cascade reagent (rCR) cartridges provide an alternative option to bolster commitments to sustainability and animal welfare WILMINGTON, Mass. / Jan 29, 2024 / Business Wire / Building upon its flagship Endosafe ® cartridge technology, Charles River Laboratories International, Inc. (NYSE: CRL) has advanced this innovation one step further and combined it with their recombinant cascade reagent... Read More

WILMINGTON, Mass. / Jan 24, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today announced the appointment of Reshema Kemps-Polanco, Executive Vice President and Chief Commercial Officer, Novartis US, to its Board of Directors. Ms. Kemps-Polanco has extensive pharmaceutical industry experience in leading commercial organizations that will provide a wealth of healthcare business leadership... Read More

WILMINGTON, Mass. / Jan 23, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) will release fourth-quarter and full-year 2023 financial results and provide 2024 guidance on Wednesday, February 14 th , before the market opens. A conference call has been scheduled to discuss this information on Wednesday, February 14 th , at 8:30 a.m. ET. Investors will have the opportunity to listen to a live... Read More

Off-the-shelf Rep/Cap simplifies gene therapy supply chains with immediate availability WILMINGTON, Mass. / Jan 16, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its off-the-shelf Rep/Cap plasmid offering, designed to streamline adeno-associated virus (AAV)-based gene therapy programs. Following the previously announced launch of its lentiviral packaging and... Read More

WILMINGTON, Mass. / Jan 08, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the 42 nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9 th , at 10:30 a.m. PST (1:30 p.m. EST). Management will present an overview of Charles River’s strategic focus, business developments, and recent trends. A live webcast of the presentation will be... Read More

Charles River’s Memphis facility approved to manufacture Vertex’s CASGEVY™ therapy, the world’s first gene-edited therapy targeting severe sickle cell disease WILMINGTON, Mass. & MEMPHIS, Tenn. / Dec 18, 2023 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today announced an important milestone in their strategic collaboration to manufacture CASGEVY ™ (exagamglogene autotemcel [exa-cel]). CASGEVY... Read More

CELLphenomics’ PD3D® tumor model platform will expand Charles River’s portfolio of 3D in vitro testing services WILMINGTON, Mass. & BERLIN / Dec 12, 2023 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into an agreement with CELLphenomics, a service-based biotechnology company that is using 3D hydrogel technology to advance the understanding of the tumor... Read More

Company will perform plasmid DNA production in support of early phase trials for SPG56 Hereditary Spastic Paraplegia WILMINGTON, Mass. / Nov 28, 2023 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) and Genetic Cures for Kids Inc (GC4K), an Australian non-profit foundation focused on research programs and clinical trials to find cures for rare diseases, today announced a plasmid DNA contract... Read More

WILMINGTON, Mass. / Nov 27, 2023 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the 6 th Annual Evercore ISI HealthCONx Conference on Wednesday, November 29 th , at 9:10 a.m. ET. Management will present an overview of Charles River’s strategic focus, business developments, and recent trends. A live webcast of the presentation will be available through a... Read More

New option for cryopreserved leukopaks supports demand of gene-modified cell therapy development and manufacturing WILMINGTON, Mass. / Nov 16, 2023 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today announced the expansion of its CliniPrime™ suite of Good Manufacturing Practice (GMP)-compliant offerings with the launch of CliniPrime Cryopreserved Leukopaks for cell therapy development and... Read More

Strategic partnership includes co-development of patient-derived xenograft (PDX) Digital Twins for in vivo oncology research Charles River to make an equity investment in Aitia as part of the agreement WILMINGTON, Mass. and SOMERVILLE, Mass. , Nov. 13, 2023 /PRNewswire/ -- Charles River Laboratories International, Inc. (NYSE: CRL) and Aitia , a leader in the application of Causal AI and Digital Twins, today announced a... Read More

WILMINGTON, Mass. / Nov 09, 2023 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of neuroscience drug discovery experts will present 19 scientific posters, both independently and collaboratively with clients, at Neuroscience 2023, the annual meeting of the Society for Neuroscience (SfN). The meeting, which brings together leading researchers from across the globe,... Read More

Third-Quarter Revenue of $1.03 Billion Third-Quarter GAAP Earnings per Share of $1.69 and Non-GAAP Earnings per Share of $2.72 Updates 2023 Guidance WILMINGTON, Mass. / Nov 08, 2023 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of 2023. For the quarter, revenue was $1.03 billion, an increase of 3.8% from $989.2 million in the third quarter of... Read More

WILMINGTON, Mass. / Oct 19, 2023 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today announced a new e-commerce ordering experience, offering clients real-time access into research model availability and pricing, as well as immediate order confirmation. The introduction of real-time ordering for Charles River’s Research Models & Services business digitizes a robust, industry-leading inventory,... Read More

WILMINGTON, Mass. / Oct 16, 2023 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) will release third-quarter 2023 financial results on Wednesday, November 8 th , before the market opens. A conference call has been scheduled to discuss this information on Wednesday, November 8 th , at 8:30 a.m. ET. Investors will have the opportunity to listen to a live webcast of the conference call through the... Read More

Recently established regulatory guidelines make testing for pediatric indications a necessary step in oncology research and development WILMINGTON, Mass. / Oct 16, 2023 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today announced the ability to conduct preclinical cancer research using ITCC-P4’s well-characterized collection of 400 annotated pediatric cancer models. As a global partner,... Read More

Company selected as Energy Star Top Project of the Year for Energy Recovery System, and develops industry partnerships to align with sustainable initiatives WILMINGTON, Mass. / Oct 11, 2023 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today announced that, while working toward previously announced environmental goals, the Company has achieved 90 percent renewable electricity globally. This... Read More

The platform can reduce lentiviral vector production timelines from 18 months to less than 7 months WILMINGTON, Mass. / Sep 26, 2023 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its lentiviral vector (LVV) manufacturing platform, Lentivation™ . The platform has the capability to reduce LVV manufacturing timelines for gene and gene-modified cell therapies by up to... Read More

RightSource is Charles River’s purpose-built lab offering that provides accessible GMP quality control testing next to the manufacturing floor STEVENAGE, United Kingdom / Sep 25, 2023 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today announced the opening of another RightSource SM facility, and first in the United Kingdom, which will provide services to the Stevenage advanced therapies... Read More

WILMINGTON, Mass. / Sep 20, 2023 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) announced that it will host a virtual Meeting with Management on Thursday, September 21 st , beginning at 8:30 a.m. ET. This virtual event will feature presentations from its senior management team, including an overview of the Company’s strategic focus, business developments, and updated financial targets, with a... Read More

Logica, an offering from Charles River and Valo Health, will be used to discover first-in-class therapeutics against high value targets in the Related Sciences portfolio WILMINGTON, Mass. & DENVER / Sep 14, 2023 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) and Related Sciences (“RS”), a data science-driven drug discovery firm, today announced a multi-program collaboration agreement to apply... Read More

WILMINGTON, Mass. / Sep 11, 2023 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at two upcoming investor conferences, including: Morgan Stanley 21 st Annual Global Healthcare Conference on Tuesday, September 12 th , at 10:10 a.m. EDT; and Baird 2023 Global Healthcare Conference on Wednesday, September 13 th , at 9:05 a.m. EDT. Management will present an... Read More

NGS assay demonstrated a broader detection range than standard in vivo tests with comparable or higher analytical sensitivity WILMINGTON, Mass. & PARIS / Sep 06, 2023 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) and PathoQuest SAS, a leader in the development and provision of next-generation sequencing (NGS) testing services for biopharmaceuticals, today announced the publication of the... Read More

HQ pDNA will be used to produce GMP lentivirus for ex vivo gene therapy WILMINGTON, Mass. / Aug 24, 2023 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL), today announced a High Quality (HQ) plasmid manufacturing collaboration with Fondazione Telethon. The rare disease organization will leverage Charles River’s market leading cell and gene contract development and manufacturing organization (CDMO)... Read More

Second-Quarter Revenue of $1.06 Billion Second-Quarter GAAP Earnings per Share of $1.89 and Non-GAAP Earnings per Share of $2.69 Updates 2023 Guidance WILMINGTON, Mass. / Aug 09, 2023 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the second quarter of 2023. For the quarter, revenue was $1.06 billion, an increase of 8.9% from $973.1 million in the second quarter of... Read More

New CRADL spaces in Seattle and Philadelphia will provide flexible vivarium space for biopharmaceutical industry WILMINGTON, Mass. / Aug 01, 2023 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) announced the planned openings of Charles River Accelerator and Development Lab (CRADL®) locations in Seattle and Philadelphia, expanding contract vivarium space for the biopharmaceutical industry. CRADL... Read More

WILMINGTON, Mass. / Jul 19, 2023 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2023 financial results on Wednesday, August 9 th , before the market opens. A conference call has been scheduled to discuss this information on Wednesday, August 9 th , at 8:30 a.m. ET. Investors will have the opportunity to listen to a live webcast of the conference call through the... Read More

New plasmids will help accelerate and standardize lentiviral vector development from clinical to commercial manufacturing WILMINGTON, Mass. / Jun 13, 2023 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its off-the-shelf lentiviral vector (LVV) packaging plasmids, providing a streamlined solution to the challenges associated with plasmid sourcing in cell and gene... Read More

Adenovirus production underpins preclinical trials targeting genes responsible for tumor growth ROCKVILLE, Md. / Jun 12, 2023 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) and Curigin , a Korean biotechnology company developing innovative oncolytic ribonucleic acid interference (RNAi) gene therapies, today announced a collaboration for adenoviral vector production. The gene therapy developer... Read More

CDMO will perform HQ plasmid production in support of Phase I/II clinical trials for Infantile Neuroaxonal Dystrophy ALDERLEY PARK, England / Jun 08, 2023 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) and the INADcure Foundation , a nonprofit organization whose mission is to support the development of treatments for Infantile Neuroaxonal Dystrophy (INAD) and other forms of PLA2G6-related... Read More

WILMINGTON, Mass. / Jun 05, 2023 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the William Blair 43 rd Annual Growth Stock Conference on Tuesday, June 6 th , at 10:00 a.m. CT (11:00 a.m. ET), and at the Jefferies Global Healthcare Conference on Thursday, June 8 th , at 11:00 a.m. ET. Management will present an overview of Charles River’s strategic focus... Read More

RightSource SM is Charles River's insourced, purpose-built lab offering that provides industry-leading expertise conveniently placed within a Wheeler Bio's new cGMP drug substance facility. OKLAHOMA CITY , May 31, 2023 /PRNewswire/ -- Wheeler Bio, Inc. , a contract development and manufacturing organization (CDMO), and Charles River Laboratories International, Inc. (NYSE: CRL) today announced an agreement to implement... Read More

RightSource is Charles River’s insourced, purpose-built lab offering that provides industry-leading expertise conveniently placed within a client’s facility WILMINGTON, Mass. / May 31, 2023 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) and Wheeler Bio, Inc., a contract development and manufacturing organization (CDMO), today announced an agreement to implement RightSource SM at Wheeler Bio’s... Read More

First-Quarter Revenue of $1.03 Billion First-Quarter GAAP Earnings per Share of $2.01 and Non-GAAP Earnings per Share of $2.78 Updates 2023 Guidance WILMINGTON, Mass. / May 11, 2023 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2023. For the quarter, revenue was $1.03 billion, an increase of 12.6% from $913.9 million in the first quarter of... Read More

Company also announces partner lab initiative to expand global coverage WILMINGTON, Mass. / May 01, 2023 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of Accugenix® Next Generation Sequencing for Bacterial Identification and Fungal Identification (Accugenix® NGS). Accugenix NGS simultaneously sequences millions of individual DNA fragments from a sample and provides... Read More

WILMINGTON, Mass. / Apr 11, 2023 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2023 financial results on Thursday, May 11 th , before the market opens. A conference call has been scheduled to discuss this information on Thursday, May 11 th , at 8:30 a.m. ET. Investors will have the opportunity to listen to a live webcast of the conference call through the Investor... Read More

Researchers highlight the importance of next-generation technologies as strategic tools for drug discovery WILMINGTON, Mass. / Apr 10, 2023 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of oncology experts will attend the American Association for Cancer Research (AACR) Annual Meeting, with 19 scientific posters and a spotlight presentation to highlight its enhanced... Read More

WILMINGTON, Mass. / Mar 13, 2023 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today launched Apollo™ , an industry-leading, secure, cloud-based platform for drug developers that provides access to study data, study milestones, documents, cost estimates, and program planning tools to save time and enhance the client experience. The platform’s current capabilities are designed to support clients... Read More

WILMINGTON, Mass. / Mar 13, 2023 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Barclays Global Healthcare Conference on Wednesday, March 15 th , at 10:15 a.m. ET. Management will present an overview of Charles River’s strategic focus and business developments. A live webcast of the presentation will be available through a link that will be posted on... Read More

WILMINGTON, Mass. / Mar 09, 2023 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its off-the-shelf pHelper offering, which is designed to secure supply and streamline adeno-associated virus (AAV)-based gene therapy programs from early discovery through commercial manufacturing. It is available immediately in Research Grade (RG), High Quality (HQ), and Good... Read More

WILMINGTON, Mass. / Feb 22, 2023 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the fourth-quarter and full-year 2022 and provided guidance for 2023. For the quarter, revenue was $1.10 billion, an increase of 21.5% from $905.1 million in the fourth quarter of 2021. The addition of a 53 rd week at the end of 2022, which is periodically required to align to a... Read More

WILMINGTON, Mass. & CAMBRIDGE, Mass. / Feb 16, 2023 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today announced a multi-program agreement with Pioneering Medicines, a strategic initiative of Flagship Pioneering, that gives Pioneering Medicines access to Logica™. Logica is an Artificial Intelligence (AI) powered drug solution that translates biological insights into optimized preclinical... Read More

WILMINGTON, Mass. / Feb 15, 2023 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) and Purespring Therapeutics , a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration. Supporting the first gene therapy platform targeting renal diseases, which affect... Read More

WILMINGTON, Mass. / Feb 13, 2023 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its first Enzyme-Linked Immunosorbent Assay (ELISA) Kit for the detection and quantitation of residual host cell proteins (HCP) in CHO-based biotherapeutics. Charles River’s HCP ELISA kit achieves industry leading rates for sensitivity and specificity, reaching 0.1 ng/mL and 90 percent... Read More

WILMINGTON, Mass. / Feb 09, 2023 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) will release fourth-quarter and full-year 2022 financial results and provide 2023 guidance on Wednesday, February 22 nd , before the market opens. A conference call has been scheduled to discuss this information on Wednesday, February 22 nd , at 8:30 a.m. ET. Investors will have the opportunity to listen to a live... Read More

Proprietary Mass Spectrometry Technology Delivering Innovative High-Throughput Screening Capabilities to Accelerate Drug Discovery Timelines Advances Partnership Initiated in 2018 WILMINGTON, Mass. / Jan 30, 2023 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has acquired SAMDI Tech, Inc , a leading provider of high-quality, label-free high-throughput screening (HTS)... Read More

CDMO partnership to provide adenoviral vector production enabling initiation of clinical trials Charles River Laboratories International, Inc. (NYSE: CRL) and Rznomics Inc. , a South Korea-based biopharmaceutical company specialized in the development of RNA-based gene therapeutics, today announced a viral vector contract development and manufacturing organization (CDMO) partnership. Rznomics will leverage Charles River’s... Read More

This initial launch includes the CliniPrime Fresh Leukopak, supporting clinical trials and commercialization of advanced therapies Charles River Laboratories International, Inc. (NYSE:CRL) today announced the launch of their new CliniPrime TM suite of Good Manufacturing Practice (GMP)-compliant cellular starting materials. CliniPrime products provide rapid access to starting materials for cell, and gene-modified cell... Read More

Company will launch the eXpDNA Platform at Phacilitate Advanced Therapies Week Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its eXpDNA™ plasmid platform, established from the Company’s contract development and manufacturing (CDMO) and biologics testing experience. The platform significantly reduces plasmid development and production timelines while streamlining the development... Read More

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the 41 st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10 th , at 10:30 a.m. PST (1:30 p.m. EST). Management will present an overview of Charles River’s strategic focus, business developments, and recent trends. A live webcast of the presentation will be available through a link that will be posted on the... Read More